By establishing a novel screening assay, we have identified inhibitors for SND1–RNA interaction and shown that the inhibition of RNA-binding sensitizes cancer cells to navitoclax, possibly by preventing the SND1-mediated miRNA degradation of tumor suppressor miR-1-3p. The gene discussed is SND1; the disease is cancer.